In this issue:
Treating early CLL with alemtuzumab and rituximab
5-year follow-up of allogeneic HCT
ALL outcomes for AYAs treated on co-operative group protocols
Early imatinib dose escalation in chronic-phase CP-CML
Prognostic markers for survival in PTLDs
Stromal gene signatures in DLBCL
Incidence and outcomes of transformed NHL
Reducing the radiotherapy field size in HL
CNS Hodgkin lymphoma
Negative predictive value of PET in residual HL
Please login below to download this issue (PDF)